PH12017500933A1 - Sublingual administration of riluzole - Google Patents

Sublingual administration of riluzole

Info

Publication number
PH12017500933A1
PH12017500933A1 PH12017500933A PH12017500933A PH12017500933A1 PH 12017500933 A1 PH12017500933 A1 PH 12017500933A1 PH 12017500933 A PH12017500933 A PH 12017500933A PH 12017500933 A PH12017500933 A PH 12017500933A PH 12017500933 A1 PH12017500933 A1 PH 12017500933A1
Authority
PH
Philippines
Prior art keywords
riluzole
sublingual administration
sublingual
disclosed
administration
Prior art date
Application number
PH12017500933A
Other languages
English (en)
Inventor
Vladimir Coric
Robert M Berman
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of PH12017500933A1 publication Critical patent/PH12017500933A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12017500933A 2014-11-21 2017-05-19 Sublingual administration of riluzole PH12017500933A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (1)

Publication Number Publication Date
PH12017500933A1 true PH12017500933A1 (en) 2017-11-20

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500933A PH12017500933A1 (en) 2014-11-21 2017-05-19 Sublingual administration of riluzole

Country Status (14)

Country Link
US (1) US20180153862A1 (enExample)
EP (1) EP3220890A1 (enExample)
JP (1) JP2017535612A (enExample)
KR (1) KR20170137030A (enExample)
CN (1) CN107735077A (enExample)
AU (1) AU2015350142A1 (enExample)
BR (1) BR112017010440A2 (enExample)
CA (1) CA2967659A1 (enExample)
EA (1) EA201791110A1 (enExample)
IL (1) IL252283A0 (enExample)
MX (1) MX2017006454A (enExample)
PH (1) PH12017500933A1 (enExample)
SG (1) SG11201703897SA (enExample)
WO (1) WO2016081466A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
RS59490B1 (sr) 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
RU2021101120A (ru) * 2016-09-15 2022-03-16 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
US10235998B1 (en) 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
CN112203692A (zh) * 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
CN112584831A (zh) * 2018-08-16 2021-03-30 拜奥海芬治疗学有限公司 利鲁唑口腔崩解片用于治疗疾病的用途
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
CA2375874A1 (en) * 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
CN109316480A (zh) * 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
IN2014DN07989A (enExample) * 2012-03-01 2015-05-01 Pharnext

Also Published As

Publication number Publication date
CN107735077A (zh) 2018-02-23
SG11201703897SA (en) 2017-06-29
EP3220890A1 (en) 2017-09-27
WO2016081466A1 (en) 2016-05-26
IL252283A0 (en) 2017-07-31
KR20170137030A (ko) 2017-12-12
JP2017535612A (ja) 2017-11-30
BR112017010440A2 (pt) 2017-12-26
EA201791110A1 (ru) 2017-11-30
US20180153862A1 (en) 2018-06-07
MX2017006454A (es) 2018-03-23
AU2015350142A1 (en) 2017-06-15
CA2967659A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
MX2017006454A (es) Administracion sublingual de riluzol.
PH12017500934B1 (en) Sublingual formulation of riluzole
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
CL2016002971A1 (es) Combinación.
TW201713333A (en) Methods of treating a neurodegenerative disease
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
NZ722600A (en) Methods of treating mild brain injury
SG10201804034QA (en) Methods for treating hypotension
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX382608B (es) Tratamiento del prurito urémico.
NZ726131A (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2016011706A (es) Formulaciones de progesterona.
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
MA40574A (fr) Traitement de maladies fibrotiques
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA104614U (uk) Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
UA91619U (uk) Спосіб підтримуючого лікування при генералізованому пародонтиті